-+ 0.00%
-+ 0.00%
-+ 0.00%

Innate Pharma Reports €56.4M Cash And €2.3M Nine-Month Revenue As Lacutamab Advances Toward TELLOMAK-3 Phase 3 Initiation In 2026

Benzinga·11/13/2025 06:18:21
Listen to the news
  • Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in Sézary syndrome
  • IPH4502 Nectin-4 ADC Phase 1 enrollment continues to progress well - pharmacologically active dose reached
  • Monalizumab PACIFIC-9 on track to deliver data in H2 2026
  • Cash position of € 56.4 million1 as of September 30, 2025, anticipated cash runway until end Q3-2026